Vasopressin belongs to the neurohypophysial hormone family, sharing structural homology with oxytocin , both are nonapeptides with a disulfide bridge between cysteine residues at positions 1 and 6. It is produced in the paraventricular and supraoptic nuclei of the hypothalamus, transported along axons to the posterior pituitary, and released into systemic circulation in response to rising plasma osmolality or significant reductions in blood volume.
The peptide acts primarily through three G-protein-coupled receptor subtypes: V1a (vascular smooth muscle and platelets), V1b (anterior pituitary corticotrophs), and V2 (renal collecting duct principal cells). Activation of V2 receptors triggers insertion of aquaporin-2 water channels into the apical membrane, increasing tubular water permeability and concentrating urine. V1a receptor activation mediates peripheral vasoconstriction, a mechanism relevant to its physiological role in haemodynamic regulation.
Synthetic analogues of vasopressin exist; desmopressin (dDAVP), a V2-selective analogue with modifications at positions 1 and 8, is a prescription-only medicine in Australia listed on the Poisons Standard. Researchers and clinicians access it through standard prescription pathways regulated by the Therapeutic Goods Administration (TGA). Other synthetic vasopressin analogues marketed outside approved pharmaceutical channels , including those sometimes promoted in performance or research contexts , are frequently unapproved therapeutic goods; supplying such products without TGA approval is illegal under the Therapeutic Goods Act 1989 (Cth) and the TGA actively enforces against unlicensed supply.
Vasopressin secretion is influenced by a range of physiological variables including ethanol (which suppresses release), nausea, pain, and certain medications. Dysregulation of the vasopressin axis is associated with distinct clinical states characterised by either excess or deficient hormone activity, studied extensively in nephrology and endocrinology literature.
Sources: